NICE Okays U.K. Coverage Of Lucentis With 14-Dose Cap; Macugen Not Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis picks up the tab for patients who need more than 14 treatments.
You may also be interested in...
Risk-Sharing Drug Rebate Contracts: Do They Live Up To The Hype?
Manufacturers and payers will continue to work on innovative pricing arrangements, roundtable panelists said, but they are likely to be less complex and resource intensive than many of the risk-sharing contracts announced to date, particularly in Europe.
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.